Clinical Trials
91 trialsTRIBE-C
Sun Yat-sen University
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
CRITâ…¡
Sixth Affiliated Hospital, Sun Yat-sen University
BEATcc
Grupo Español de Investigación en Cáncer de Ovario
AMBITION
Japanese Foundation for Cancer Research
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Sun Yat-sen University
BCTOP-T-M01
Fudan University
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
SOLARIS
Alliance for Clinical Trials in Oncology
FOBEAR
Sun Yat-sen University
BRAINS
The Netherlands Cancer Institute
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
TALENTOP
Fudan University
BASKETâ…¢
Sixth Affiliated Hospital, Sun Yat-sen University
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
AtezoTRIBE2
Gruppo Oncologico del Nord-Ovest
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
Zhejiang Cancer Hospital
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer
Sun Yat-sen University
BRADI
Institut Cancerologie de l'Ouest
COLAGE
GERCOR - Multidisciplinary Oncology Cooperative Group
OSCAR
Federation Francophone de Cancerologie Digestive
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Tongji Hospital
REGTAS-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
MRD-GI
Georgetown University
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
ATALANTE
ARCAGY/ GINECO GROUP
CAIRO5
Dutch Colorectal Cancer Group
ITACa
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
CR-SEQUENCE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
PHARBEVACOL
University Hospital, Tours
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
Shengjing Hospital
BECOME
Hunan Province Tumor Hospital
STRATEGIC-1
GERCOR - Multidisciplinary Oncology Cooperative Group
CAIRO4
Dutch Colorectal Cancer Group
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System
SELENIUM
Seoul National University Hospital
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
Sixth Affiliated Hospital, Sun Yat-sen University
OBELICS
National Cancer Institute, Naples
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Samsung Medical Center
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Spanish Breast Cancer Research Group
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
MITO16MANGO2b
National Cancer Institute, Naples